Vivek Kumar, BS; Jason Kessler, MD, MPH; Elisabeth J. Cohen, MD
Disclosures: Authors have disclosed no conflicts of interest. Forms can also be viewed at www.acponline.org/authors/icmje/Conflict OfInterestForms.do?msNum=L15-0586.
Kumar V., Kessler J., Cohen E.; Zoster Vaccination for Persons Aged 50 to 59 Years. Ann Intern Med. 2016;164:850. doi: 10.7326/L15-0586
Download citation file:
Published: Ann Intern Med. 2016;164(12):850.
TO THE EDITOR:
Le and Rothberg's recent analysis (1) supports the Centers for Disease Control and Prevention recommendation for herpes zoster (HZ) vaccine for immunocompetent people aged 60 years or older, despite U.S. Food and Drug Administration approval since 2011 for use in adults aged 50 years or older. We would like to counter these arguments and explain why physicians should recommend this vaccine to eligible persons aged 50 years or older.
The authors based their analysis on the assumption that the incidence of HZ would plateau after either 2010 or 2015. However, evidence suggests that HZ incidence continues to increase and is modeled to increase for 50 years (2). Earlier vaccination is more efficient against increasing HZ incidence.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only